C4X Discovery Holdings plc has outlicensed its once daily oral NRF2 (Nuclear factor-erythroid factor 2-related factor 2) activator to Astrazeneca plc in a deal with a potential value of $402 million.
• Activation of nuclear factor erythroid 2-related factor 2 (Nrf2) significantly reduces the accumulation of senescent bronchial epithelial cells in chronic obstructive pulmonary disease (COPD) models ...
This is a preview. Log in through your library . Abstract The transcription factor Nrf2 is an important modulator of antioxidant and drug metabolism, carbohydrate and lipid metabolism, as well as heme ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results